Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez

New Updates in Frontline DLBCL

Scripps Health

L. Nastoupil

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial

Wojciech Jurczak

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

Tara Graff

Will Immune Therapy Replace Transplant in Hematologic Malignancies?

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

R. Gale

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment

Total Health

J. Chandler, B. Randolph, M. Onciu

ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Randomized …

Insights from 2023 ASCO® Annual Meeting

J. Westin

Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC

Georg Lenz

FDA Approval of Epcoritamab in R/R FL: What You Need to Know

Yasmin Karimi

Current Management of DLBCL From Frontline to Relapsed Disease

Dipenkumar Modi

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu

Tafasitamab + Lenalidomide vs. CIT for Transplant-Ineligible R/R DLB…

Patrizia Mondello